Skye Bioscience Inc (SKYE)

Apr 23, 2025

Skye Bioscience stock target holds at $15 on obesity drug outlook - Investing.com

Apr 23, 2025

Apr 22, 2025

William Blair Forecasts Skye Bioscience Q2 Earnings - MarketBeat

Apr 22, 2025

Apr 22, 2025

(04/22/25) SKYE: A Speculative Play in the Weight Loss Drug Space - moneyshow.com

Apr 22, 2025

Apr 21, 2025

SKYE’s Market Ups and Downs: What’s Behind the 2023 Stock Performance? - investchronicle.com

Apr 21, 2025

Apr 19, 2025

Skye Bioscience, Inc. (NASDAQ:SKYE) Given Average Rating of “Buy” by Analysts - Defense World

Apr 19, 2025

Apr 19, 2025

William Blair Predicts Skye Bioscience Q1 Earnings - Defense World

Apr 19, 2025

Apr 19, 2025

Brokers Offer Predictions for Skye Bioscience Q1 Earnings - Defense World

Apr 19, 2025

Apr 19, 2025

Analysts Set Skye Bioscience, Inc. (NASDAQ:SKYE) PT at $16.60 - Defense World

Apr 19, 2025

Apr 18, 2025

Brokers Issue Forecasts for Skye Bioscience Q2 Earnings - Defense World

Apr 18, 2025

Apr 16, 2025

A Weight Loss Drug Candidate Essentially For Free As Skye Bioscience Is Trading At Cash Value - Seeking Alpha

Apr 16, 2025

Apr 15, 2025

Mural's Big Shake-Up, Skye's Weight Loss Win, And Janover's Crypto Bet - Finimize

Apr 15, 2025

Apr 15, 2025

Skye Bioscience reports promising obesity treatment study By Investing.com - Investing.com South Africa

Apr 15, 2025

Apr 15, 2025

Skye Bioscience's Obesity Candidate Shows 30% Weight Loss When Combined With Eli Lilly's Blockbuster Drug In Animal Models - Benzinga

Apr 15, 2025

Apr 15, 2025

Skye Bioscience (SKYE) Schedules Key Meetings at Biopharma Symposium - GuruFocus

Apr 15, 2025

Apr 15, 2025

Crude Oil Moves Lower; Citigroup Posts Upbeat Results - Benzinga

Apr 15, 2025

Apr 15, 2025

Skye Bioscience soars after experimental weight-loss drug shows promise in mice - TradingView

Apr 15, 2025

Apr 15, 2025

Nasdaq Surges 100 Points; Bank of America Earnings Top Views - Benzinga

Apr 15, 2025

Apr 15, 2025

Skye Bioscience Demonstrates Over 30% Weight Loss With Nimacimab And Tirzepatide Combination In Preclinical Model - marketscreener.com

Apr 15, 2025

Apr 15, 2025

Skye Bioscience's (SKYE) Nimacimab Shows Promising Weight Loss R - GuruFocus

Apr 15, 2025

Apr 15, 2025

Skye Bioscience Demonstrates Over 30% Weight Loss with Nimacimab - GuruFocus

Apr 15, 2025

Apr 15, 2025

Skye Bioscience Demonstrates Over 30% Weight Loss with Nimacimab and Tirzepatide Combination in Preclinical Model | SKYE Stock News - GuruFocus

Apr 15, 2025

Apr 15, 2025

Skye Bioscience reports promising obesity treatment study - Investing.com

Apr 15, 2025

Apr 15, 2025

Skye Bioscience Demonstrates Over 30% Weight Loss with - GlobeNewswire

Apr 15, 2025

Apr 15, 2025

Skye Bioscience (SKYE) Demonstrates Over 30% Weight Loss with Nimacimab and Tirzepatide Combination in Preclinical Model - StreetInsider

Apr 15, 2025

Apr 15, 2025

Revolutionary Obesity Drug Combo Shows 30% Weight Loss Success in Latest Trial Data - Stock Titan

Apr 15, 2025

Apr 15, 2025

Skye Bioscience to Conduct Meetings at Piper Sandler Conference - GuruFocus

Apr 15, 2025

Apr 14, 2025

Major Obesity Drug Developer Skye Bio Takes Center Stage at Prestigious Investor Conference - Stock Titan

Apr 14, 2025

Apr 11, 2025

Skye Bioscience (NASDAQ:SKYE) Shares Down 50.8% – Here’s Why - Defense World

Apr 11, 2025

Apr 11, 2025

Skye Bioscience (NASDAQ:SKYE) Trading Down 50.8% – What’s Next? - Defense World

Apr 11, 2025

Apr 08, 2025

Skye Bioscience, Inc. Investigated by Shareholder Rights AdvocatesInvestors Should Contact Levi & Korsinsky Regarding Potential Securities Law ViolationsSKYE - ACCESS Newswire

Apr 08, 2025

Apr 02, 2025

Charles Schwab Investment Management Inc. Has $176,000 Position in Skye Bioscience, Inc. (NASDAQ:SKYE) - Defense World

Apr 02, 2025

Apr 02, 2025

Charles Schwab Investment Management Inc. Grows Stock Position in Skye Bioscience, Inc. (NASDAQ:SKYE) - Defense World

Apr 02, 2025

Apr 02, 2025

10,142 Shares in Skye Bioscience, Inc. (NASDAQ:SKYE) Acquired by Virtu Financial LLC - Defense World

Apr 02, 2025

Apr 02, 2025

Virtu Financial LLC Invests $29,000 in Skye Bioscience, Inc. (NASDAQ:SKYE) - Defense World

Apr 02, 2025

Mar 30, 2025

Skye Bioscience, Inc. (NASDAQ:SKYE) Receives Consensus Rating of “Buy” from Analysts - Defense World

Mar 30, 2025

Mar 30, 2025

Skye Bioscience, Inc. (NASDAQ:SKYE) Receives $18.00 Average Price Target from Analysts - Defense World

Mar 30, 2025

Mar 28, 2025

Skye Bioscience, Inc. (NASDAQ:SKYE) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat

Mar 28, 2025

Mar 25, 2025

Skye Bioscience, Inc. (PNK:SKYE) Q4 2024 Earnings Call Transcript - MSN

Mar 25, 2025

Mar 25, 2025

Skye Bioscience (NASDAQ:SKYE) Receives Outperform Rating from William Blair - MarketBeat

Mar 25, 2025

Mar 25, 2025

Skye Bioscience promotes Tu Diep to COO post - The Pharma Letter

Mar 25, 2025

Mar 25, 2025

Skye Bioscience (NASDAQ:SKYE) Price Target Cut to $14.00 by Analysts at Craig Hallum - MarketBeat

Mar 25, 2025

Mar 24, 2025

Skye Bioscience (NASDAQ:SKYE) Announces Quarterly Earnings Results - MarketBeat

Mar 24, 2025

Mar 23, 2025

Skye Bioscience’s SWOT analysis: novel obesity drug stock faces pivotal year - Investing.com Canada

Mar 23, 2025

Mar 23, 2025

Craig Hallum Cuts Skye Bioscience (NASDAQ:SKYE) Price Target to $14.00 - Defense World

Mar 23, 2025

Mar 23, 2025

Skye Bioscience’s (SKYE) “Outperform” Rating Reiterated at William Blair - Defense World

Mar 23, 2025

Mar 23, 2025

Craig Hallum Issues Pessimistic Forecast for Skye Bioscience (NASDAQ:SKYE) Stock Price - Defense World

Mar 23, 2025